In the rapidly evolving field of oncology, the development of advanced anti-tumor therapeutics continues to offer new hope for patients battling various forms of cancer. As global healthcare systems ...

Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial. Sequential ...

1 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China 2 Department of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China ...

This study, known as ESPAC4, reported on with long-term follow-up of 732 patients in a phase 3, open-label, multicentre, randomised clinical trial of GemCap vs gemcitabine. Patients were seen in 92 ...

A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study showed. In ...

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX ...

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...

Patients who received gemcitabine followed by docetaxel experienced a delay in the need for radical cystectomy. Sequential intravesical gemcitabine/docetaxel treatment for high-risk nonmuscle-invasive ...

No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. In this phase 3, multinational, ...

Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy. Radiation induced lymphopenia in unilateral versus bilateral radiochemotherapy ...